TWTing-Ting Wang

Ting-Ting Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ting-Ting Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Wang

    Sun Yat-sen University Cancer Center 1 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China

    1 shared publication
  • Hai-Yu Mo

    Sun Yat-sen University Cancer Center 1 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China

    1 shared publication
  • Hao-Jie Chen

    State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

    1 shared publication
  • Huai-Qiang Ju

    State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    1 shared publication
  • Jia-Jun Li

    The First Affiliated Hospital of Zhengzhou University 3 Provincial Key Laboratory of Radiation Medicine in Henan Zhengzhou, P. R. China

    1 shared publication
  • Kun Liao

    State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

    1 shared publication

Latest Publications

  • PLA1A Inhibition Enhances Chemoimmunotherapy Efficacy by Blocking Immunosuppressive Macrophage Polarization in Colorectal Cancer

    by Ting-Ting Wang, Wei-Shuai Kong, Jia-Jun Li, Ying-Yu Qiu, Ren-Ze Huang, Hao-Jie Chen, Xiao-Tong Duan, Ping Chen, Yi-Chen Xie, Hai-Yu Mo, et al.

    Clinical outcomes are often suboptimal in patients with colorectal cancer treated with neoadjuvant chemotherapy (NAC). A key determinant of the response to NAC is the functional state of tumor-infiltrating immune cells. Understanding how NAC reshapes the immunologic landscape will be essential for refining patient stratification and identifying effective combination treatment strategies. In this study, we analyzed paired samples before and after NAC treatment by single-cell RNA sequencing (scRNA-seq), revealing that NAC treatment significantly reshaped the immune microenvironment. Tumors from NAC nonresponders featured increased immunosuppressive M2-like macrophage infiltration, which correlated with elevated phosphatidylserine-specific phospholipase A1 (PLA1A). Mechanistically, PLA1A hydrolyzed phosphatidylserine (PS) exposed by chemotherapy to elevate lysophosphatidylserine (LysoPS), which activated the P2ry10 receptor and downstream signaling to promote M2-like macrophage polarization. Importantly, pharmacologic inhibition of PLA1A by cilengitide synergized with chemoimmunotherapy to suppress tumor progression in murine models. Clinically, high plasma PLA1A levels negatively correlated with responses to chemoimmunotherapy. Collectively, these findings reveal a chemotherapy-driven metabolic axis that induces an immunosuppressive milieu by increasing LysoPS release. This axis highlights PLA1A as a therapeutic target to mitigate immunosuppression and improve chemoimmunotherapy efficacy. Significance: Chemotherapy-resistant colorectal cancer elevates PLA1A to induce anti-inflammatory macrophage polarization, supporting the potential of PLA1A as a therapeutic target for enhancing chemoimmunotherapy efficacy and as a biomarker of treatment response.